CINECA IRIS Institutional Research Information System

FERRERO, Simone
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.175
EU - Europa 4.101
AS - Asia 2.370
SA - Sud America 179
OC - Oceania 102
AF - Africa 64
Continente sconosciuto - Info sul continente non disponibili 4
Totale 11.995
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.009
IT - Italia 1.410
CN - Cina 821
SG - Singapore 416
IE - Irlanda 378
SE - Svezia 371
FR - Francia 293
DE - Germania 265
GB - Regno Unito 248
JP - Giappone 241
AT - Austria 206
KR - Corea 201
IN - India 142
FI - Finlandia 124
DK - Danimarca 111
TR - Turchia 111
UA - Ucraina 107
ES - Italia 98
VN - Vietnam 96
AU - Australia 91
CA - Canada 83
BR - Brasile 78
MX - Messico 68
PL - Polonia 66
CH - Svizzera 65
NL - Olanda 64
TH - Thailandia 63
HK - Hong Kong 55
BE - Belgio 54
RU - Federazione Russa 47
GR - Grecia 46
ID - Indonesia 45
PT - Portogallo 37
CL - Cile 30
NO - Norvegia 28
MY - Malesia 26
TW - Taiwan 25
CZ - Repubblica Ceca 24
SN - Senegal 21
CO - Colombia 20
IL - Israele 20
IR - Iran 20
AR - Argentina 19
PE - Perù 19
SA - Arabia Saudita 18
PK - Pakistan 16
PH - Filippine 14
UZ - Uzbekistan 12
NZ - Nuova Zelanda 11
BY - Bielorussia 9
LT - Lituania 9
EG - Egitto 8
KZ - Kazakistan 8
AW - Aruba 7
MA - Marocco 7
RO - Romania 7
ZA - Sudafrica 7
EC - Ecuador 6
HR - Croazia 6
BG - Bulgaria 5
DZ - Algeria 5
GH - Ghana 5
RS - Serbia 5
EE - Estonia 4
EU - Europa 4
OM - Oman 4
PR - Porto Rico 4
SI - Slovenia 4
SK - Slovacchia (Repubblica Slovacca) 4
BD - Bangladesh 3
BO - Bolivia 3
HU - Ungheria 3
KW - Kuwait 3
NG - Nigeria 3
PS - Palestinian Territory 3
VE - Venezuela 3
BH - Bahrain 2
GT - Guatemala 2
LV - Lettonia 2
MU - Mauritius 2
SC - Seychelles 2
TN - Tunisia 2
AE - Emirati Arabi Uniti 1
CU - Cuba 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
IQ - Iraq 1
JO - Giordania 1
LU - Lussemburgo 1
MM - Myanmar 1
MN - Mongolia 1
TG - Togo 1
UY - Uruguay 1
Totale 11.995
Salva come PNG Salva come JPEG
Città #
Chandler 621
Santa Clara 402
Dublin 372
Beijing 328
Singapore 325
Torino 262
Ashburn 245
Fairfield 242
Vienna 196
Ann Arbor 191
Houston 152
Wilmington 152
Nyköping 143
Turin 136
Dearborn 116
Woodbridge 116
Villeurbanne 113
Medford 109
Florence 94
Cambridge 93
Princeton 93
Columbus 91
Seattle 88
Milan 87
Rome 87
Redwood City 79
San Mateo 77
Jacksonville 71
Guangzhou 61
Tokyo 61
Fremont 58
Boston 51
Munich 51
Dong Ket 49
Helsinki 44
Jakarta 44
Shanghai 44
Pisa 43
Sydney 43
New York 41
Washington 40
Bologna 34
Warsaw 34
Chennai 30
Istanbul 30
London 30
Toronto 28
Brussels 27
Hangzhou 25
Ankara 24
Barcelona 24
Nanjing 24
Hebei 23
São Paulo 23
Naples 21
Oslo 21
San Diego 21
Chengdu 20
Lima 19
Madrid 19
Santiago 19
Bangkok 18
Boardman 18
Central 18
Melbourne 17
Mumbai 17
Norwalk 17
Zurich 17
Berlin 16
Los Angeles 16
Frankfurt am Main 15
Kuala Lumpur 15
Osaka 15
Philadelphia 15
Rochester 15
Seoul 15
Guiyang 14
Taipei 14
Athens 13
Atlanta 13
Lisbon 13
Paris 13
Bengaluru 12
Brno 12
Genoa 12
Newburyport 12
Ottawa 12
Padova 12
Palermo 12
San Jose 12
Zhengzhou 12
Amsterdam 11
Belo Horizonte 11
Brisbane 11
Lausanne 11
Manchester 11
Moscow 11
Mountain View 11
Bogotá 10
Hat Yai 10
Totale 6.736
Salva come PNG Salva come JPEG
Nome #
Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi 1.434
ABVD vs BEACOPP escalated in advanced-stage Hodgkin’s lymphoma: Results from a multicenter European study 1.316
Early progression as a predictor of survival in marginal zone lymphomas: An analysis from the FIL-NF10 study 419
HashClone: a new tool to quantify the minimal residual disease in B-cell lymphoma from deep sequencing data 392
Maternal and Perinatal Outcomes of Pregnant Women with SARS-COV-2 infection 291
Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma 266
Novel CALR somatic mutations in essential thrombocythaemia 243
Minimal residual disease in mantle cell lymphoma: are we ready for a personalized treatment approach? 238
Highly sensitive MYD88 l265p mutation detection by droplet digital polymerase chain reaction in waldenström macroglobulinemia 206
Prospective molecular monitoring of minimal residual disease after nonmyeloablative allografting in newly diagnosed multiple myeloma 205
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis 199
Centralized Biobanking Supports Hematology Clinical Trials: the new challenge of the University of Torino 195
A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the "Fondazione Italiana Linfomi" MCL-0208 trial 177
A 6-GENE EXPRESSION SIGNATURE IN MANTLE CELL LYMPHOMA: RESULTS FROM THE FONDAZIONE ITALIANA LINFOMI (FIL)-MCL-0208 TRIAL 161
Applying data warehousing to a phase III clinical trial from the Fondazione Italiana Linfomi (FIL) ensures superior data quality and improved assessment of clinical outcomes. 137
High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma 134
New Molecular Technologies for Minimal Residual Disease Evaluation in B-Cell Lymphoid Malignancies 132
KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study 125
Psychological distress and oral chemotherapy: a pilot study. 124
High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma 123
Telomere length is an independent predictor of survival, treatment requirement and Richter’s syndrome transformation in chronic lymphocytic leukemia 115
Ficoll-hypaque separation vs whole blood lysis: Comparison of efficiency and impact on minimal residual disease analysis 114
Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi 113
Characteristics of the Immunoglobulin Heavy Chain (IgH) Rearrangement in Multiple Myeloma (MM): An Analysis On 308 Cases 112
COMPREHENSIVE ANALYSIS OF BASELINE OUTCOME BIOPREDICTORS IN YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: THE ANCILLARY BIOLOGICAL STUDIES OF FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 CLINICAL TRIAL 112
Droplet digital PCR for minimal residual disease detection in mature lymphoproliferative disorders 109
Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR 107
Delphi, a Data Warehouse to Discover Associations between Variables in Clinical Trials: Application to the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial 107
Italian real life experience with ibrutinib: Results of a large observational study on 77 relapsed/refractory mantle cell lymphoma 107
Correlation Between Clinical Outcome and Disease Kinetics by Quantitative PCR in Myeloma Patients Following Post-Transplant Consolidation with Bortezomib, Thalidomide and Dexamethasone 104
Expression of telomeric proteins in chronic lymphocytic leukemia (CLL) 103
A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines 103
MYD88L265P MUTATION DETECTION IN WALDENSTRÖM MACROGLOBULINEMIA BY DROPLET DIGITAL PCR: MINIMAL RESIDUAL DISEASE MONITORING AND CHARACTERIZATION ON CIRCULATING FREE DNA 102
Real life use of bendamustine in elderly patients with lymphoid neoplasia 100
High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma 98
Telomere Length Is An Independent Predictor of Survival, Treatment Requirement and Richter’s Syndrome Transformation in Chronic Lymphocytic Leukemia 97
Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival 96
The Engineered MIPI (e-MIPI), a Candidate Data-Mining Based Mantle Cell Lymphoma Prognostic Index Developed from the Dataset of the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial 96
Oral chemotherapy: an innovative choice 92
Droplet Digital PCR Assay for MYD88L265P 91
Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: Evidences from long term follow-up 88
Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia 87
Consolidation with Bortezomib, Thalidomide and Dexamethasone Induces Molecular Remissions in Autografted Multiple Myeloma Patients 85
MYC Rearranged Aggressive B-Cell Lymphomas: A Report on 100 Patients of the Fondazione Italiana Linfomi (FIL) 84
LONG-TERM RESULTS of the GIMEMA VTD Consolidation TRIAL In Autografted MULTIPLE Myeloma PATIENTS (VEL-03-096): IMPACT of Minimal RESIDUAL DISEASE Detection by REAL Time Quantitative PCR On LATE Recurrences and Overall SURVIVAL 83
Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network 83
Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes 82
Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation 82
Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia 80
Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders 80
Minimal Residual Disease in Indolent Lymphomas: A Critical Assessment 79
Real life clinical outcomes of relapsed/refractory diffuse large B cell lymphoma in the rituximab era: the STRIDER study 78
Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study 77
Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death 77
Major Shrinking of Residual Tumor Cell Burden and Achievement of Molecular Remissions in Myeloma Patients Undergoing Post-Trasplant Consolidation with Bortezomib, Thalidomide and Dexamethasone: A Qualitative and Quantitative PCR Study 76
A targeted mutational landscape of angioimmunoblastic T-cell lymphoma 73
Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin’s lymphoma: evidence from a multicenter, retrospective study 72
A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL) 72
Application of the Euro Clonality next-generation sequencing-based marker screening approach to detect immunoglobulin heavy chain rearrangements in mantle cell lymphoma patients: first data from the Fondazione Italiana Linfomi MCL0208 trial 72
Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells 72
Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi 71
Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: Final results of a European MCL Network Phase II Trial 69
Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial 69
Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma 67
PERSONALIZED MEDICINE IN LYMPHOMA: TAILORING TREATMENT ACCORDING TO MINIMAL RESIDUAL DISEASE 66
Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option? 66
Minimal residual disease detection in lymphoma and multiple myeloma: impact on therapeutic paradigms 65
null 64
HIGH RATES OF PROLONGED MOLECULAR REMISSIONS AFTER TANDEM AUTOLOGOUS-NONMYELOABLATIVE ALLOGRAFTING IN NEWLY DIAGNOSED MYELOMA 63
Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase III trial in mantle cell lymphoma 62
Droplet digital PCR quantification of mantle cell lymphoma follow-up samples from four prospective trials of the european MCL network 61
COVID-19 in a Post-transplant Heart Recipient Who Developed Aggressive Lymphoma: A Biphasic Course During Rituximab Treatment 61
Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: A phase II clinical trial of the fondazione italiana linfomi 57
Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study 56
Mantle Cell Lymphoma of Mucosa-Associated Lymphoid Tissue 55
Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies 54
Dissecting MRD Kinetics By Automated Computational Analysis to Improve Outcome Prediction in Mantle Cell Lymphoma: A Bioinformatic Substudy from the Fondazione Italiana Linfomi (FIL) MCL0208 Clinical Trial 53
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease 53
Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. 51
Allogeneic stem cell transplantation in mantle cell lymphoma in the era of new drugs and CAR-T cell therapy 51
A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi 50
Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma 49
Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma 48
MYD88L265P Detection in IgM Monoclonal Gammopathies: Methodological Considerations for Routine Implementation 48
The challenge of treating elderly patients with mantle cell lymphoma 47
ACCELERATE: A Patient-Powered Natural History Study Design Enabling Clinical and Therapeutic Discoveries in a Rare Disorder 43
HBV Reactivation in Patients with Past Infection Affected by Non-Hodgkin Lymphoma and Treated with Anti-CD20 Antibody Based Immuno-Chemotherapy: A Multicenter Experience 42
How to treat old MCL patients: One size fits it all? 41
A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial 40
Quality Assessment for PCR-based Minimal Residual Disease in Lymphoma: 10 Years of Cross-laboratory Standardization Process Within the Fondazione Italiana Linfomi MRD Network 39
The role of targeted treatment in mantle cell lymphoma: Is transplant dead or alive? 38
Dichotomic response to interleukin-6 blockade in idiopathic multicentric Castleman disease: two case reports 38
The current therapeutic scenario for relapsed mantle cell lymphoma 36
Personalized medicine in lymphoma: Is it worthwhile? The mantle cell lymphoma experience 36
Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma. 30
How to manage mantle cell lymphoma 30
Efficacy of rituximab in anti-myelin-associated glycoprotein demyelinating polyneuropathy: Clinical, hematological and neurophysiological correlations during 2 years of follow-up 29
Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the Fondazione Italiana Linfomi MCL0208 trial 29
Molecular remission is an independent predictor of progression-free survival in patients with Waldenström macroglobulinemia treated with chemo-immunotherapy: Results from the FIL_BIOWM study 26
Nucleic Acid Biomarkers in Waldenström Macroglobulinemia and IgM-MGUS: Current Insights and Clinical Relevance 25
Totale 12.155
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.081
article - articoli 0
book - libri 0
conference - conferenze 6.455
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.536
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020741 0 0 0 0 0 138 103 83 106 97 118 96
2020/20211.314 125 75 141 64 121 77 75 82 124 102 110 218
2021/20221.817 79 68 110 164 114 109 202 109 86 175 355 246
2022/20232.628 208 224 76 230 224 534 211 193 265 145 142 176
2023/20241.957 161 260 150 131 214 251 119 148 19 110 133 261
2024/20251.983 171 212 285 349 719 247 0 0 0 0 0 0
Totale 12.328